Role of Rho kinase in sphingosine 1-phosphate-mediated endothelial and smooth muscle cell migration and differentiation.
The role of sphingosine 1-phosphate (S1P)-induced Rho kinase (ROCK) activation in the angiogenic responses of pulmonary artery-derived endothelial cells (PAEC) and smooth muscle cells (PASMC) was examined. S1P, a biologically active phospholipid that regulates angiogenesis, promoted PAEC chemotaxis and capillary morphogenesis; furthermore, this activity was unaltered by pretreatment with the pharmacological inhibitor of ROCK, H1152. In contrast, S1P (500 nM) significantly inhibited spontaneous PASMC chemotaxis and differentiation; however, this inhibition was eradicated upon H1152 pretreatment. Similarly, PASMCs transfected with ROCK II siRNA diminished S1P-induced inhibition of the development of multi-cellular structures. Analysis by RT-PCR identified the presence of S1P(1) and S1P(3) receptors on both PAECs and PASMCs, while S1P(2) receptor expression was confined to only PASMCs. Consistent with this observation, the S1P(1) and S1P(3) receptor antagonist, VPC23019, virtually abolished the S1P-initiated PAEC differentiation but did not impede the S1P-induced inhibition of PASMC differentiation. However, the S1P(2) receptor antagonist, JTE013, had no effect on S1P-mediated differentiation of PAECs but abolished the S1P-induced inhibition of PASMC function. Co-cultured endothelial and smooth muscle cells differentiated into "neovascular-like" networks, which were significantly inhibited by S1P. The inhibition of co-culture differentiation in both PAECs and PASMCs was negated by H1152 pretreatment. However, when smooth muscle cells were added to S1P-initiated endothelial cell networks, additional S1P treatment did not inhibit the cellular networks generated by these cells. In conclusion, S1P-induced PAEC angiogenic responses are regulated by S1P(1) and/or S1P(3) receptors independent of Rho kinase activation, whereas S1P(2) receptor-mediated curtailment of PASMC function by S1P.
Harvey
Kevin A
KA
Cellular Biochemistry Laboratory, Methodist Research Institute, Clarian Health Partners, Room E504, Indianapolis, IN, USA.
Welch
Zachary
Z
Sliva
Daniel
D
Siddiqui
Rafat A
RA
D015153:Blotting, Western; D002454:Cell Differentiation / Q000187:drug effects*; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation; D002633:Chemotaxis; D018920:Coculture Techniques; D004730:Endothelium, Vascular / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D008246:Lysophospholipids / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000166:cytology* / Q000378:metabolism; D018919:Neovascularization, Physiologic; D010766:Phosphorylation; D011651:Pulmonary Artery / Q000166:cytology; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000494:pharmacology; D049349:Receptors, Lysosphingolipid / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000502:physiology*
D008246:Lysophospholipids; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D049349:Receptors, Lysosphingolipid; C060506:sphingosine 1-phosphate; D054460:rho-Associated Kinases; D013110:Sphingosine
Circulation. 2007 Jan 30;115(4):501-8
17242282
Hypertension. 2007 Oct;50(4):792-8
17785632
Cell. 1999 Oct 29;99(3):301-12
10555146
Circulation. 1998 Feb 3;97(4):381-90
9468212
Angiogenesis. 2001;4(1):11-20
11824373
Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R440-6
16990495
J Biol Chem. 2003 Nov 28;278(48):47654-9
14500721
J Biol Chem. 2002 Feb 22;277(8):6214-22
11739394
Mol Cell Neurosci. 1994 Jun;5(3):201-9
8087418
Am J Physiol Gastrointest Liver Physiol. 2006 Oct;291(4):G605-10
16675745
Circ Res. 2006 Oct 13;99(8):837-44
16990566
J Biol Chem. 2000 May 12;275(19):14281-6
10799507
J Biol Chem. 2005 Mar 18;280(11):9833-41
15590668
Am J Respir Cell Mol Biol. 2001 Jun;24(6):711-9
11415936
Nat Rev Mol Cell Biol. 2003 Jun;4(6):446-56
12778124
J Biol Chem. 1999 Dec 10;274(50):35343-50
10585401
Exp Cell Res. 2002 Apr 1;274(2):264-74
11900487
Eur J Clin Invest. 2007 Mar;37(3):171-9
17359484
J Lab Clin Med. 2002 Sep;140(3):188-98
12271276
Curr Pharm Des. 2006;12(5):575-87
16472149
Biochem Biophys Res Commun. 1996 Oct 14;227(2):608-14
8878560
Genomics. 1998 Oct 15;53(2):164-9
9790765
Biochim Biophys Acta. 2002 May 23;1582(1-3):72-80
12069812
J Cardiovasc Pharmacol. 2007 Aug;50(2):195-200
17703136
Biochem J. 2000 Jul 15;349(Pt 2):385-402
10880336
J Biol Chem. 2004 Oct 8;279(41):42422-30
15292266
J Biol Chem. 1992 Jun 5;267(16):10931-4
1375931
FASEB J. 2003 Oct;17(13):1931-3
14519669
Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):69-75
12524227
J Cell Physiol. 2007 May;211(2):353-63
17167780
Pharmacol Ther. 2000 Nov;88(2):115-31
11150592
J Clin Invest. 2004 Feb;113(4):569-81
14966566
J Biol Chem. 1990 Jun 5;265(16):9308-13
2160972
Circ Res. 2007 Mar 30;100(6):923-9
17332430
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1312-8
17431187
J Allergy Clin Immunol. 2009 Nov;124(5):933-41.e1-9
19665772
J Mol Med (Berl). 2002 Oct;80(10):629-38
12395147
Biochem J. 2000 Dec 15;352 Pt 3:809-15
11104690
Cancer Res. 2005 May 1;65(9):3788-95
15867375
Circ Res. 2004 Feb 20;94(3):385-93
14670839
FASEB J. 2000 Nov;14(14):2255-65
11053247
Am J Physiol Cell Physiol. 2004 May;286(5):C1130-8
15075212
Pharmacol Ther. 2002 Feb-Mar;93(2-3):225-32
12191614
J Immunol. 2003 Nov 15;171(10):5489-97
14607955
Biochem Biophys Res Commun. 2006 May 19;343(4):1038-44
16574065